The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 08, 2016

Filed:

Jan. 15, 2013
Applicant:

Sbi Pharmaceuticals Co., Ltd., Minato-ku, Tokyo, JP;

Inventors:

Tohru Tanaka, Tokyo, JP;

Kiwamu Takahashi, Tokyo, JP;

Motowo Nakajima, Minato-ku, JP;

Fuminori Abe, Tokyo, JP;

Masahiro Ishizuka, Tokyo, JP;

Urara Ota, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/195 (2006.01); G01N 33/72 (2006.01); G01N 33/574 (2006.01); G01N 33/70 (2006.01); A61K 49/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/72 (2013.01); A61K 49/0036 (2013.01); G01N 33/574 (2013.01); G01N 33/70 (2013.01); G01N 2800/7028 (2013.01);
Abstract

It is to provide a tumor diagnostic agent and a tumor determination method enabling not only determination of the presence or absence of a tumor in a subject, but also determination of whether the tumor is a malignant tumor or a benign tumor, which can be used simply at low cost with reduced side effects and burden. 5-aminolevulinic acid (ALA) or its derivative, or a salt thereof is orally administered at a dose of 5 to 7 mg in terms of ALA per kg of body weight, and a urine sample 4 to 12 hours after the administration is collected. Porphyrins and creatinine in the urine sample are quantitated, and based on the value (nmol/gCre) obtained by dividing the amount of porphyrins by the amount of creatinine, a distinction among an individual without a tumor, an individual with a benign tumor, and an individual with a malignant tumor is determined. The presence or absence of a malignant tumor in a subject can be clearly determined by administering 1 to 3 mg of ALAs in terms of ALA per kg of body weight.


Find Patent Forward Citations

Loading…